Recent advances in cirrhotic cardiomyopathy

Area of Science:

• Cardiology
• Hepatology
• Pharmacology

Background:

• Cirrhotic cardiomyopathy is a recognized cardiac dysfunction in cirrhosis patients.
• It presents with altered diastolic relaxation, impaired contractility, and electrophysiological abnormalities like QT prolongation.

Purpose of the Study:

• To review the pathogenesis, clinical manifestations, and prognostic implications of cirrhotic cardiomyopathy.
• To discuss current understanding and potential future therapeutic strategies.

Main Methods:

• Literature review of cirrhotic cardiomyopathy.
• Analysis of pathogenetic mechanisms including beta-receptors, transmembrane currents, and cardiodepressant factors.
• Evaluation of clinical presentation, diagnostic features, and prognostic impact.

Main Results:

• Diastolic dysfunction is an early sign, followed by systolic incompetence, often unmasked by stress.
• QT interval prolongation occurs in ~50% of patients, rarely causing fatal arrhythmias.
• Impaired cardiac function is linked to poorer survival, especially during procedures like TIPS or liver transplantation.

Conclusions:

• Cirrhotic cardiomyopathy significantly impacts survival rates in cirrhosis patients.
• No specific treatment currently exists, but future therapies may target underlying pathogenetic mechanisms.
• Further research into novel therapeutic agents is warranted.